Can replacing biased blood-forming stem cells alone deliver lasting benefits against aging?
Replacing 90% of myeloid-biased long-term hematopoietic stem cells—blood-forming cells biased toward myeloid output—with balanced-output cells is proposed to suffice through year 20. Stable balanced donor–host output without multidomain and survival benefit would falsify the claim.
Omega Point 1.1
Stage of verification
- Hypothesis published2026-09-18
- Indirect evidenceAssessed at 5 of 10
- Direct testAwaited
Map of the hypothesis
Hover over an icon or tap it to see its name.
Where in the body
Biological function
Kind of knowledge gap
A double ring marks the main placement where a group contains several values.
Target map
Every target of every published hypothesis, each with the actions a hypothesis can propose on it. The targets and the actions of this hypothesis are drawn solid.
Stem cell
Myeloid-biased long-term hematopoietic stem cells
Long-term blood-forming stem cells with myeloid-biased output
Where this hypothesis actsThroughout axial and proximal appendicular marrow in the baseline stem-cell compartment
Hypotheses on this target 1
Reprogramming
Transplantation1
Directed differentiation
Proliferation
Population balance
What is proposed
Transplantation
Replace 90% of the myeloid-biased compartment with balanced-output stem cells
With whatCell therapy
HowSelective depletion and transplantation in one initial event; preserve balanced host HSCs, marrow mesenchymal stroma, thymic epithelium, and all nonhematopoietic tissues
Possible result
Possible sustained balanced blood-cell output and prevention of immune-metabolic recovery deficits over 20 years
From the recordreplace 90% of the baseline functionally identified myeloid-biased long-term hematopoietic stem-cell compartment throughout axial and proximal appendicular marrow with balanced-output long-term hematopoietic stem cells.
All targets of the lab
Every target read from the published hypotheses, each kind around its pictogram. A larger mark means more hypotheses act on that target. Point at a mark and the actions proposed on it branch out of it.
Solid and named: the targets of this hypothesis
Explore in depth
The logic
The train of thought that ends in this hypothesis. Each stage is the reason the next exists. The master question narrows to a goal, the goal to an unknown nobody has closed, the unknown to the hypothesis proposed here. Every step below says what it rests on and what carries it.
Most proposals for slowing aging by tissue replacement begin with the organs that visibly fail — hearts, kidneys, muscles. This one discards all of them. It proposes that replacing a single population of blood-forming stem cells in the bone marrow, and nothing else, is the entire sufficient intervention, and that below a sharp 90-percent displacement threshold the benefit is lost entirely because the remaining biased clones reclaim the compartment. This claim was generated by the reasoning chain below, drawing on invasion ecology and clonal competition as its framing — no experiment has tested it.
- Myeloid-biased long-term hematopoietic stem cells — blood-forming stem cells that preferentially produce inflammatory innate-immune cells over adaptive-immune cells — accumulate in bone marrow with age, displacing balanced-output stem cells.
- A single transplantation procedure clears 90 percent of these biased incumbent stem cells from marrow throughout the spine and upper-limb bones and replaces them with balanced-output long-term hematopoietic stem cells.
- The transplanted balanced cells, now holding 90 percent of the long-term stem-cell compartment, outcompete the remaining 10 percent of biased incumbents for the limited niche space in the marrow.
- With biased clones unable to regain dominance, the marrow sustains balanced production of both myeloid and lymphoid blood cells — maintaining adaptive immunity alongside innate immunity — without further intervention.
- Balanced immune output prevents the chronic low-grade inflammation and weakened immune surveillance that otherwise accumulate across every organ over decades.
- Multi-organ aging driven by this immune-metabolic dysfunction is slowed without replacing tissue in any non-hematopoietic organ — the blood system's correction propagates the benefit body-wide.
A factory's quality-control department has been gradually taken over by inspectors who only check for one kind of defect and ignore all others. Rather than repairing every product line downstream, you replace 90 percent of these narrow inspectors with versatile ones who catch the full range of problems. If you leave too many of the old inspectors in place, they fill the open shifts again within a few years and the factory is back where it started.
Where the picture breaks: Factory inspectors do not compete with one another for a limited number of desks the way stem cells compete for niche space, and the factory floor is not itself altered by which inspectors are working. In bone marrow, the niche — the microenvironment that houses and signals to stem cells — ages on its own and may selectively favor the biased cells regardless of how many balanced cells are introduced. The picture also hides the cost of clearing the old inspectors: in biology, the conditioning regimen needed to remove incumbent stem cells carries its own damage.
- Master questionstep 01 of 04
The question is what minimum amount of tissue, measured in grams and as a fraction of each organ's functional units, would need to be replaced to slow aging and extend lifespan in a person.
Rests on: The premise that aging can in principle be slowed by replacing specific tissues, and that a minimum sufficient set exists that is smaller than replacing everything.
AssumptionIt is assumed that a minimum sufficient tissue-replacement set exists — that aging is not so globally distributed across cell types that only whole-body replacement or no replacement at all could work.
- Goal pillarstep 02 of 04
The goal is to identify the specific tissues, their cumulative mass, and the fraction of each functional unit that constitutes the minimum replacement set needed to meet the master question's criteria.
Rests on: The master question's demand for both identity — which parts — and quantity — how much.
Stated in the chain - Gap questionstep 03 of 04
After experimentally reducing candidate replacement fractions and schedules to the lowest levels that still work, how many cumulative grams per person and what percentage of each functional unit remain necessary over a twenty-year horizon — accounting for tissue growth and any repeat procedures — and where do the minima for different tissues create conflicts with one another?
Rests on: The goal pillar's requirement to find minimum quantities. This step operationalizes that requirement by asking for the residual numbers after systematic reduction testing and by surfacing where optimizing one tissue's fraction worsens another's.
Stated in the chain - Hypothesisstep 04 of 04
Replacing 90 percent of the myeloid-biased long-term hematopoietic stem cells — blood-forming stem cells that preferentially produce innate-immune cells — throughout the spine and upper-limb bone marrow with balanced-output long-term hematopoietic stem cells, in a single procedure with no repetition over twenty years, constitutes the entire sufficient tissue-replacement set. No muscle, organ, fat, thymic epithelium (the tissue that trains adaptive immune cells), or bone marrow stroma (the support scaffolding around stem cells) needs replacing. The claim is that persistent balanced blood-cell output prevents immune and metabolic deficits from accumulating across all organs, and that below 90 percent replacement the remaining biased clones regain dominance and the benefit is lost.S1S2S5S6
Rests on: The gap question's demand for specific tissue identities, quantities, and schedules. The biological premise — that myeloid-biased hematopoietic stem cells accumulate with age, that this shift drives hematopoietic dysfunction, and that interventions targeting the stem-cell compartment can partially reverse aging phenotypes — is drawn from the screened literature.
Supported by literature
What is carried, and what is not. Six of the nine screened sources speak to at least one link in the chain. The biological premise — that myeloid-biased hematopoietic stem cells accumulate with age and contribute to hematopoietic dysfunction — is established across multiple mouse studies (S1, Nature Aging, 2026; S2, Nature Communications, 2024; S3, eLife, 2025; S4, S7, S8). Two sources go further: S5 (Cell Research, 2025) shows that reducing dysfunctional high-CD150 hematopoietic stem cells attenuates aging phenotypes in irradiated old recipient mice, and S6 (Aging Cell, 2020) shows that transplanting young-donor hematopoietic stem cells extends lifespan in mice at roughly 15–21 percent chimerism. But no source tests the 90-percent displacement threshold, no source examines whether balanced hematopoietic output alone — without any other tissue replacement — prevents multi-organ aging, no source follows outcomes for anything approaching twenty years, and every experiment uses mice. The sequence as a whole — from stem-cell replacement through immune-metabolic correction to body-wide aging suppression — has no direct experimental precedent in any species.S1S2S3S4S7S8S5S6
Where the reasoning is carried by something unstated · 1
- Master question. It is assumed that a minimum sufficient tissue-replacement set exists — that aging is not so globally distributed across cell types that only whole-body replacement or no replacement at all could work.
How a result here could mislead · 3
- Early blood counts may normalize after transplant regardless of whether balanced donor stem cells have truly outcompeted the biased incumbents in the marrow, because even low-level or transient engraftment can produce balanced peripheral blood ratios for months. A positive early result could reflect temporary engraftment rather than the durable competitive dominance the hypothesis requires. What closes it: Serial clonal tracking — using barcoded or lineage-traced donor cells — must confirm that donor-derived balanced clones maintain or expand their share of the marrow stem-cell compartment over the full observation period, not merely that peripheral blood ratios appear balanced at sampled time points.
- The conditioning regimen required to clear 90 percent of incumbent biased stem cells — whether irradiation, chemotherapy, or targeted depletion — itself damages and remodels the bone marrow niche. Any subsequent improvement in blood output or organ function could reflect niche remodeling from the conditioning rather than the balanced-output properties of the transplanted cells. What closes it: A control arm receiving identical conditioning followed by transplantation of an equivalent number of aged myeloid-biased stem cells, and a second arm receiving conditioning alone with no transplant, are both required. If either control arm shows comparable early benefit, the balanced-output claim has not been separated from the conditioning effect.
- A negative result — no multi-organ benefit despite stable balanced chimerism — would be ambiguous between two conclusions: that balanced hematopoietic output genuinely does not prevent organ aging, and that the intervention came too late because organ damage accumulated before transplantation is irreversible regardless of subsequent blood composition. What closes it: The experiment must include a cohort receiving the same intervention at a younger age, where less organ damage has accumulated. A negative result in the older cohort paired with a positive result in the younger cohort would point to timing rather than mechanism, while negative results in both would weigh against the hypothesis itself.
What would make this wrong. The chain breaks if myeloid-biased hematopoietic stem cell accumulation is predominantly a consequence of systemic aging rather than a driver of it — if replacing biased stem cells restores balanced blood output but organs continue aging at the same rate because the dominant damage pathways are cell-autonomous within each tissue, not mediated through the immune-metabolic signals the blood system delivers.
What it would change. If this held, the search for a minimum tissue-replacement set to slow aging would collapse from a multi-organ engineering problem to a single-compartment transplantation problem. Researchers pursuing muscle, kidney, liver, or cardiac tissue replacement as anti-aging strategies would confront the claim that none of those tissues need replacing if the blood-forming compartment is corrected first. Even then, what would remain unestablished is whether mouse-to-human translation preserves the effect, whether twenty-year durability is achievable without repeat intervention in a human marrow niche that ages on its own timeline, and whether the conditioning required to clear 90 percent of incumbent stem cells introduces morbidity and mortality risk that offsets the longevity benefit.
Sources read · 9
Shear stress governs hematopoietic stem cell fate to promote inflammation-induced aging. · Nature aging · 2026
“In mice and humans, at least two sub-populations of mainly quiescent HSCs exist postnatally: 1) balanced and lymphoid-biased HSCs that dominate in early life, and 2) myeloid-biased HSCs that dominate in old age in protective microenvironments or niches.”
Does not settle: Whether replacing myeloid-biased HSCs with balanced-output HSCs delivers lasting anti-aging benefits is not addressed. The source covers myeloid-bias accumulation with age and its link to clonal expansion and pre-cancer evolution, but reports no replacement, transplantation, or competitive-repopulation experiments. It does not address sufficiency of any replacement threshold, durability of balanced output over years, downstream organ-level effects, or the 90%-displacement criterion. Its frame is disease initiation and therapeutic resistance in malignancy, not anti-aging intervention.
Aging is associated with functional and molecular changes in distinct hematopoietic stem cell subsets. · Nature communications · 2024
“age-related molecular changes were primarily observed in HSCs and not propagated to progenitors, suggesting that aging mechanisms preferentially target HSCs. This also implies that it could be sufficient to target HSCs to restore age-related hematopoietic dysfunction.”
Does not settle: The source characterises intrinsic myeloid-bias changes in mouse HSC subsets and infers that targeting HSCs might suffice, but it performs no replacement experiment and reports no lasting-benefit outcome. It does not test whether physical replacement (versus in-situ correction) of biased clones works, does not address any engraftment threshold (the 90% figure is entirely unexamined), does not measure downstream organ or immune-metabolic endpoints, and all data are from C57BL/6J mice across timescales of months — not the 20-year human horizon the question posits. Whether balanced-output HSCs can outcompete incumbent biased clones after transplantation, and whether doing so prevents systemic aging deficits, is not addressed.
Alteration of long- and short-term hematopoietic stem cell ratio causes myeloid-biased hematopoiesis. · eLife · 2025
“the ratio of long-term hematopoietic stem cell (LT-HSC) versus short-term HSC (ST-HSC) determines the lineage output of HSCs and reduced ratio of ST-HSC in aged mice causes myeloid-biased hematopoiesis”
Does not settle: The retrieved text is almost entirely a reference list and peer-review commentary rather than the paper's main results section, so the actual experimental evidence cannot be evaluated directly. The paper's core claim—that myeloid bias arises from an altered LT-HSC:ST-HSC ratio rather than from intrinsically biased LT-HSCs—is conveyed only through a reviewer's summary, and that reviewer flags the evidence as incomplete and the sample sizes as insufficient. The paper does not test any replacement intervention; it does not address whether transplanting balanced-output LT-HSCs would restore ratio-corrected output, whether 90 % chimerism is required for durable correction, what happens in aged (vs. young) recipient niches, or whether results translate from mouse to human or across a 20-year timeframe. The eLife assessment explicitly calls the conclusions incomplete.
Lack of MDA5 delays hematopoietic aging by modulating inflammaging and proteostasis in mice. · Nature communications · 2026
“Other studies showed that aged HSCs are refractory to systemic rejuvenation intervention delivered via the blood stream . In another study, the microbiome/IL-1/IL-1R1 axis was proven to be key for hematopoietic aging, and manipulation of this axis could lead to better repopulation capacity and reversal of myeloid bias”
Does not settle: The source studies intrinsic MDA5 ablation as a means of delaying myeloid bias and HSC aging in mice; it does not test competitive replacement of the myeloid-biased LT-HSC compartment with balanced-output cells, report on any replacement-fraction threshold (let alone 90%), address durability of benefit over a multi-year or 20-year horizon, examine whether balanced-donor HSCs can sustain dominance against residual incumbent biased clones, or assess downstream immune-metabolic organ endpoints. All findings are in mice, not humans. The transplantation experiments referenced are serial competitive repopulation assays, not a therapeutic replacement model. Whether intrinsic HSC modification transfers mechanistically to cell-replacement scenarios is not addressed.
Reducing functionally defective old HSCs alleviates aging-related phenotypes in old recipient mice. · Cell research · 2025
“reducing the dysfunctional CD150 high HSCs can attenuate aging phenotypes in old recipient mice, highlighting that the removal of defective CD150 high HSCs from old mice could be a potential strategy for rejuvenation”
Does not settle: All experiments are in mice (2–24 months), not humans. Replacement requires myeloablative lethal irradiation as conditioning, so selective non-myeloablative displacement of the biased compartment is untested. Observation windows are months, not years, so durability equivalent to 20 years is not established. The 90% replacement threshold and the question of whether residual incumbent biased clones regain dominance over time are not addressed. The source uses young donor HSCs or CD150-low-selected old HSCs, not a defined 'balanced-output' population, so the specific product proposed in the question is not tested. Multi-organ immune-metabolic endpoints beyond blood chimerism and epigenetic age are cut off in the provided text window. Whether the benefit is attributable to displacement of biased clones versus paracrine or systemic signals from young donor cells is not resolved.
Mobilization-based transplantation of young-donor hematopoietic stem cells extends lifespan in mice. · Aging cell · 2020
“We speculate that these health‐associated benefits are a consequence of replacing actively proliferating myeloid‐biased HSCs known to accumulate in aged mice (reviewed in (Kovtonyuk et al., )), subsequently decreasing their contributions to LSK frequencies and myeloid cells in the peripheral blood and thus relieving symptoms of immunosenescence.”
Does not settle: The question's core threshold claim — that ≥90% replacement is required for lasting benefit and that <90% allows incumbent biased clones to regain dominance — is not tested. Achieved donor chimerism was only ~15–21% of lineage-negative bone marrow cells, explicitly described as 'limited replacement' that 'partially ameliorated' aged phenotypes, not fully corrected them. The source therefore cannot confirm whether 90% is the necessary or sufficient threshold. It also leaves open: (1) whether partial chimerism is self-sustaining or reverts over longer timescales, since follow-up was 4 months post-transplant; (2) 20-year durability in any species; (3) applicability to humans — only female mice were used; (4) whether benefits arise from balanced lineage output specifically, or from other cell-nonautonomous effects of young donor cells on the aged niche; (5) the effect of transplanting aged rather than young donor HSCs; and (6) sex-generalizability within even the mouse model.
SIRT3 reverses aging-associated degeneration. · Cell reports · 2013
“SIRT3 upregulation rescues functional defects of aged HSCs We next determined whether SIRT3 upregulation is sufficient to rescue the functional defects of aged HSCs and reverse aging-associated degeneration.”
Does not settle: The source addresses intrinsic HSC quality decline via SIRT3/oxidative-stress pathways in mice; it does not address myeloid-biased versus balanced-output clonal composition, competitive replacement of HSC subpopulations, the 90% replacement threshold, whether transplanting balanced LT-HSCs prevents immune-metabolic aging across organs, or durability of any intervention over a 20-year horizon. All findings are in mouse models (18–24-month-old C57BL/6), not humans. The mechanism studied (mitochondrial ROS via SIRT3-SOD2) is orthogonal to clonal competition dynamics.
Temporal inhibition of autophagy reveals segmental reversal of ageing with increased cancer risk. · Nature communications · 2020
“combined these results suggest that the general WBC expansion is driven by systemic autophagy loss, while the myeloid skewing is immune cell intrinsic.”
Does not settle: The source does not test replacement of myeloid-biased HSCs with balanced HSCs, does not address whether correcting HSC output bias alone would prevent multi-organ aging accumulation, does not speak to any threshold (90% or otherwise) of clone replacement, does not assess durability beyond 4 months of observation, uses autophagy-deficient bone marrow as a proxy for myeloid bias rather than clonal competition among normal HSC subtypes, and is conducted entirely in mice — human translation, timescales out to year 20, and non-hematopoietic tissue effects of HSC-only intervention are all unaddressed.
USP7 sustains hematopoietic stem cell homeostasis partially via PU.1 stabilization. · International journal of biological sciences · 2026
“Usp7- deficient HSPCs, comprising LT-HSCs, ST-HSCs, MPPs, GMPs, MEPs and CMPs, also exhibited a dramatic reduction (Fig. C). We subsequently investigated the impact of USP7 ablation on normal hematopoiesis under conditions of hematopoietic stress. Sequential 5-FU challenge assay revealed that Scl-Cre ; Usp7 fl/fl mice died dramatically earlier than Usp7 fl/fl mice”
Does not settle: The source does not address aging-associated myeloid bias in HSCs, clonal competition between myeloid-biased and balanced-output LT-HSC populations, the 90% replacement threshold, durability of balanced output after competitive transplantation, or any aging or immune-metabolic endpoint. Its competitive transplantation data concern a USP7-knockout disease model rather than the natural clonal dynamics of aged marrow. PU.1's role in myeloid differentiation is noted but not linked to the question of whether correcting population composition prevents accumulation of downstream organ deficits. Species studied are mice only; human relevance is unaddressed. The source establishes no threshold, timeline, or outcome pertinent to the SCOUT hypothesis.
The gap this hypothesis explains
Nothing is known here: the question has not been asked of this system.
How much replacement tissue is needed per organ over twenty years to slow aging?
Original wording · exactly as the pipeline generated it
How many cumulative grams per person and what percentages of each named functional unit remain necessary after experimental fraction and schedule reduction, counting growth and repeats over 20 years, and where do these minima conflict?
What this question is asking
This question asks whether anyone has calculated the minimum cumulative mass of replacement tissue — broken down by organ or functional unit — that a person would need to receive over a twenty-year period to measurably slow biological aging. It wants not just a single number but a schedule: how much of each tissue type at each timepoint, accounting for the fact that transplanted or engineered tissue grows, fuses with host tissue, and may need to be replaced again. It also asks where the minimums for different organs conflict with each other — for instance, whether reducing the amount replaced in one organ forces a larger replacement in another, creating trade-offs with no single best solution.
- functional unit
- The smallest structurally and functionally self-contained piece of an organ — for example, a liver lobule or a kidney nephron. The question asks what percentage of these units in each organ would need to be replaced, recognizing that organs are not homogeneous masses but collections of repeating modules, each of which contributes a share of the organ's total function.
- cumulative grams
- The total mass of replacement tissue delivered to a person over the entire twenty-year period, summed across all procedures. This is distinct from a single-procedure dose because tissue delivered early may grow, degrade, or need re-replacement, so the lifetime total is not simply the first dose multiplied by the number of sessions.
- Pareto frontier (nondominated trade-offs)
- A concept from multi-objective optimization describing the set of solutions where improving one objective necessarily worsens another. In this context, it would be the set of replacement schedules where reducing the amount replaced in one organ cannot be done without increasing it in another — there is no schedule that is strictly better in every dimension. The question asks where these trade-offs arise.
- RL-2 lineage accounting
- A framework referenced in the gap detail for tracking how replacement tissue behaves after transplantation — whether it survives, expands, fuses with host tissue, or is lost. No returned source defines or uses this term, so it may be an internal project designation rather than a widely published method.
- ranking-reversal tolerance
- The amount of uncertainty in a measurement or estimate that would be large enough to change the ordering of options — for instance, if the uncertainty in two organs' replacement doses overlaps enough that it is unclear which truly needs more. The question demands that accounting uncertainty stay below this threshold so that the ranking of organs by replacement need is reliable.
- engraftment and integration
- The process by which transplanted or engineered tissue becomes structurally and functionally incorporated into the recipient organ. Engraftment refers to the tissue surviving and establishing a blood supply; integration refers to it connecting with surrounding cells and performing its intended function. Both processes are incomplete and variable, which is why the question must account for losses.
- tissue replacement for aging
- The broad concept of periodically introducing young or engineered tissue into aging organs to restore function. This is distinct from conventional organ transplantation, which replaces a failed organ once. The question envisions a program of repeated partial replacements over decades, more like maintenance than rescue, and asks what the minimum effective program would look like.
RL-2 lineage accounting and Pareto methods coexist with observed growth and fusion effects and can in principle yield outcome-qualified minimum quantities for tissue replacement.
The question assumes that a specific analytical framework — referred to as 'RL-2 lineage accounting' — already exists and can track how replacement tissue behaves after transplantation (whether it grows, merges with existing tissue, or degrades), and that multi-objective optimization methods (Pareto analysis) can then identify the smallest effective doses. It needs this to be true because without an existing accounting method, the question of 'how much is the minimum' has no framework in which to be answered. The question also assumes that growth and fusion of replacement tissue have been experimentally observed, making dose accounting non-trivial.
No source was read against this question, so nothing can be said about its premise. No sources were returned by the search, so there is no evidence in the read material either establishing or refuting the existence of an 'RL-2 lineage accounting' framework, Pareto-based dose optimization for tissue replacement, or experimentally measured growth and fusion parameters for replacement tissue in an aging context. The premise cannot be evaluated from the available search results.
The same question asked without the part nothing read establishes:
- Has anyone estimated how much replacement tissue each major organ would need over a multi-decade period to produce a measurable slowing of age-related functional decline?
- What experimental data exist on how transplanted or engineered tissue grows, integrates, or degrades over years in human organs, and do those data allow cumulative dose calculations?
- Are there multi-objective optimization studies that identify trade-offs between replacing different tissues to maximize lifespan benefit while minimizing total surgical burden?
- Calculable minimums exist and do not conflict across organs If each organ's minimum replacement dose can be independently determined and the minimums do not interfere with one another, a single optimal replacement schedule could be specified. This would allow clinical trial design with fixed dosing protocols and would make cost and risk estimation straightforward, since each organ's program could be planned in isolation.
- Calculable minimums exist but conflict across organs If reducing the replacement burden for one organ demands increasing it for another — for example, if replacing less liver tissue requires compensatory kidney replacement to maintain clearance — then no single schedule is optimal. Designers would face a Pareto frontier of trade-offs, and choosing among them would require value judgments about which organs matter most, making the program inherently personalized rather than standardized.
- Growth and integration variability makes stable minimums incalculable If transplanted tissue grows, fuses, or degrades at rates too variable across individuals or too poorly measured to predict, then a fixed twenty-year dose cannot be specified in advance. The replacement program would need to be adaptive — monitored and adjusted at each timepoint — and any upfront calculation of cumulative grams would be unreliable, undermining the premise that a minimum can be identified at all.
Any program of periodic tissue replacement to slow aging must eventually specify doses — how many grams of liver, how many grams of thymus, how often — or it remains a thought experiment. Without cumulative quantity estimates that account for growth, integration losses, and repeat procedures, it is impossible to compare competing replacement strategies on cost, surgical burden, or immunological risk. Acting on the wrong schedule could mean either replacing too little tissue to produce a measurable effect or replacing far more than necessary, exposing patients to avoidable procedural harm and immune suppression.
RL-2 lineage accounting and Pareto methods coexist with observed growth and fusion effects; no outcome-qualified minimum quantity is established.
Determine qualifying cumulative grams and unit-specific percentages over at least 20 years, with accounting uncertainty below prespecified ranking-reversal tolerances.
Unknown dose, expansion, and repeat requirements prevent identification of either minimum or their nondominated trade-offs.
The mechanism it proposes
The engine's own statement of the hypothesis, in full.
SCOUT candidate from invasion ecology and somatic clonal competition: replace90%of the baseline functionally identified myeloid-biased long-term hematopoietic stem-cell compartment throughout axial and proximal appendicular marrow with balanced-output long-term hematopoietic stem cells. Retain balanced host HSCs, marrow mesenchymal stroma, thymic epithelium, and all nonhematopoietic tissues. One initial event and no repeat through year 20 are hypothesized sufficient. The sufficient set is the competing stem-cell population, not total marrow: persistent balanced output prevents immune-metabolic recovery deficits from accumulating across organs. Replacement below90%leaves enough incumbent biased clones to regain dominance and therefore fails long-term qualification.
Testing and possible results
The prediction that would tell it apart
A hypothesis that predicts what its rivals predict is not worth running an experiment over. This is the observation on which this one differs.
Selective90%replacement qualifies without thymic, stromal, adipose, muscular, or visceral replacement. Lower replacement fractions show later resurgence of baseline biased clones and lose clinical qualification despite comparable early blood counts. Depletion alone and transplantation without sufficient incumbent replacement fail to match the complete strategy. Stable balanced chimerism without multidomain and survival benefit falsifies the sufficiency claim.
Would tell it apart from at least one rival. The prediction states qualitative comparative outcomes and an explicit falsification condition. No rival prediction is supplied. A paper already fetched for this hypothesis bears on it.
What testing it would take
The engine's own read on whether this is testable with methods that already exist.
Aged-animal depletion, transplantation, and serial clonal assays can test competitive replacement. Human myeloid bias is not reliably defined by a single universal marker, and selective low-harm replacement at this coverage is unestablished. Conditioning and infection risks are part of the strategy's outcomes.
What stands behind it
Which of the figures above have a study behind them, which are the engine's own, and what it would take to refute the hypothesis. This audit never judges the idea.
3 quantitative figures appear below and the hypothesis cites no study for any of them. They are the engine's own, and the marks in the text say which.
What it would take to refute it. 2 paper(s) already retrieved for this hypothesis carry its prediction’s terms. Reading them comes before running anything. Already retrieved: Meat Nutritional Value and Exoskeleton Valorisation of <i>Callinectes sapidus</i> from Three Sites of Biological and Ecological Interest in Morocco: Scientific Insights Toward a Management Strategy in the Mediterranean Sea.; Pea Breeding for Resistance to Rhizospheric Pathogens..
6 papers retrieved around this hypothesis
- Pea Breeding for Resistance to Rhizospheric Pathogens.PMID 36235530 · full_text · 158,871 characters stored
- Publication Onlyeuropepmc:PMC:PMC13254489 · full_text · 1,268 characters stored
- Meat Nutritional Value and Exoskeleton Valorisation of <i>Callinectes sapidus</i> from Three Sites of Biological and Ecological Interest in Morocco: Scientific Insights Toward a Management Strategy in the Mediterranean Sea.PMID 41003336 · full_text · 108,944 characters stored
- Abstracts from the 57th European Society of Human Genetics (ESHG) Conference: Hybrid Posterseuropepmc:PMC:PMC11627200 · full_text · 951 characters stored
- Abstracts from the 54<sup>th</sup> European Society of Human Genetics (ESHG) Conference: e-Posters.PMID 35393538 · full_text · 983 characters stored
- UEG Week 2024 Poster Presentationseuropepmc:PMC:PMC11470995 · full_text · 1,120 characters stored
0 citation handles extracted; 1 Europe PMC search run; 7 records examined; 6 sources stored for enrichment, 6 with full text. A citation that did not resolve is a bibliographic failure, not proof that no such paper exists, and no hypothesis is blocked by this audit.